



This is a repository copy of *Research and policy impact of trials published by the UK National Institute of Health Research (2006-2015)*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/158739/>

Version: Accepted Version

Article:

Carroll, C. orcid.org/0000-0002-6361-6182 and Tattersall, A. (2020) Research and policy impact of trials published by the UK National Institute of Health Research (2006-2015). *Value in Health*, 23 (6). pp. 727-733. ISSN 1098-3015

<https://doi.org/10.1016/j.jval.2020.01.012>

Article available under the terms of the CC-BY-NC-ND licence
(<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>



**Research and policy impact of trials published by the UK
National Institute of Health Research (2006-2015)**

Journal:	<i>Value in Health</i>
Manuscript ID	VIH-2019-0692.R2
Article Type:	Health Policy Analysis
Health Areas List:	Other health conditions < Health Areas
Methods of Interest List:	Health Policy: database study < Methods of Interest, Health Policy: methods < Methods of Interest
Keywords Enter Your Own:	Health policy; Impact; Randomised controlled trials; Systematic review

SCHOLARONE™
Manuscripts

1
2
3 TITLE: Research and policy impact of trials published by the UK National Institute of Health Research (2006-
4 2015)

5
6
7
8
9 Funding:

10 This work received no funding.

11
12
13 Keywords:

14 Health policy; Impact; Randomised controlled trials; Systematic review

15
16
17 Original article

18
19
20 Running title:

21 Impact of UK NIHR clinical trials
22
23
24
25
26

27 HIGHLIGHTS

- 28
29
- 30 • The instrumental use of a randomised controlled trial in systematic reviews and policy and guidance
31 documents represents an easily quantifiable but important dimension of impact
 - 32 • This analysis has found that randomised controlled trials funded by the NIHR and published in the
33 HTA journal series and related journals have impressive citation rates and a sizeable proportion are
34 certainly being used in key publications in a genuinely instrumental manner.
35
36
- 37
38
39

40 Concise summary:

41 Randomised controlled trials funded and published by the NIHR have impressive citation rates and many are
42 used in research and policy in an instrumental manner.
43
44

45 Total number of pages= 15; total number of tables=2; total number of figures=2.

46
47
48 Word count=3987
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ABSTRACT:
4

5
6 OBJECTIVES:
7

8 Health Technology Assessment (HTA) aims to inform and support healthcare decision-making and trials are part
9 of that process. The purpose of this study was to measure the impact of a sample of trials in a meaningful but
10 robust fashion.
11
12
13

14
15 METHODS: All randomised controlled trials funded and published by the UK National Institute of Health
16 Research (NIHR) in the Health Technology Assessment journals series and other peer-reviewed journals were
17 identified for 2006-2015. Citation analysis was performed for all trials, and quantitative content analysis
18 undertaken on a purposive sample to determine if impact could be categorised as 'instrumental', i.e. having a clear
19 influence on key research and policy publications.
20
21
22
23

24
25 RESULTS:
26

27
28 The search identified 133 relevant trials. Citation rate per trial was 102.97. 129/133 (98%) of trials were cited in
29 one or more systematic reviews or meta-analyses (mean per trial 7.18, range 0-44). Where they were cited, the
30 trials were used in some form of synthesis 63% of the time. 91/133 (68%) of trials were found to be cited in one
31 or more guidance or policy document (mean per trial 2.75, range 0-26), and had an instrumental influence 41%
32 of the time. The publication of these trials' results in journals other than the Health Technology Assessment journal
33 appears to enhance the discoverability of the trial data. Altmetric.com proved to be very useful in identifying
34 unique policy and guidance documents.
35
36
37
38
39
40

41
42 CONCLUSION:
43

44
45 These trials have impressive citation rates and a sizeable proportion are certainly being used in key publications
46 in a genuinely instrumental manner.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

I. INTRODUCTION

Health Technology Assessment (HTA) aims to inform and support healthcare decision-making¹. Randomised controlled trials are part of that process. They have an inherent value in that they provide an answer to a question where previously there had been uncertainty (equipose). However, ‘value’ is a much-debated and multi-dimensional concept and a randomised controlled trial’s value must extend beyond providing an answer to a question. It should have some demonstrable impact too². However, assessing the impact of research presents many problems. First, there are many available models for doing so, but all have limitations^{3,4}. Second, there is the definition of the term ‘impact’ itself. The measurement of impact can range from counting the number of times a piece of research is cited by others, to its generation of social, economic or health benefits beyond academia^{3,5}. The former, the simple citation of research, is now recognised as a rather limited metric of either impact or quality^{6,7}; it does not indicate how the research was used or its possible level of influence on other research⁸. The latter, the demonstration of benefits beyond academia, is undoubtedly more meaningful, but is also more difficult to determine. Consequently, there is potential value in examining not only those publications that are citing the research, but also how they are using it. In this way, it is possible to generate more meaningful data, while also exploring the broader impact of research.

This study aims to show that a particular approach to analysing citation data can provide greater insight into the impact of a particular body of research. In the payback framework of impact, a link is made between the primary and secondary outputs of research, in other words, between the original journal article and its use by other outputs.^{3,9} In the case of randomised controlled trials, relevant secondary outputs include, most obviously, policy and guidance documents, but also systematic reviews and meta-analyses¹⁰, which represent an influential form of evidence in the production of much policy and guidance^{11,12,13}. Indeed, current published research on this topic has recognised that, ‘there is merit in using existing systematic reviews to assess the impact of trials’¹⁰ and that this knowledge gap remains to be filled. The trials funded by the UK National Institute of Health Research (NIHR) represent an obvious sample on which to conduct this work. This funder has previously sought to gauge the impact of the research it funds, for UK HTA projects generally, based on numbers of publications, basic citation analysis or a small number of individual case studies, testing authors’ perceptions of the impact of their research^{10,14}. This has included an evaluation of the use and weighting of some HTA trials in meta-analyses in Cochrane’s reviews¹⁰, but not their use in non-Cochrane reviews, other types of synthesis, or in policy or guidance documents. The aim of the present research is to extend this previous work by quantifying the impact of randomised controlled trials,

published in the NIHR Health Technology Assessment journal, based on the use of these trials in specific types of citing publication: systematic reviews and meta-analyses, and policy and guidance documents.

II. METHODS

Sample

This study is a citation analysis, with quantitative content analysis, of a sample of randomised controlled trials published in the NIHR Health Technology Assessment (HTA) journal. The HTA monograph is a peer-reviewed, open-access journal. Each issue is dedicated to a single project, such as a randomised controlled trial. To be included in the sample for this analysis, the publication had to be a randomised controlled trial funded by the UK NIHR and published in the HTA journal series from 2006 to 2015. A 10-year period of publications was chosen to enable the creation of a sizeable sample with substantial citation data; this would minimise the chance of findings being heavily skewed by results from a single year or a small group of atypical publications, and also controlled for potential long-term impact³. The date limit of 2015 permitted sufficient time for included trials to have generated citations up to the point of this analysis. To identify these trials, a search was conducted in MEDLINE, which fully indexes the HTA journal, for randomised controlled trials on any topic published in the HTA journal series from 2006 to 2015 inclusive. The results were then screened using the inclusion criteria described above and the following publication types were excluded: pilot, exploratory or feasibility trials; and studies evaluating methods of recruitment to trials. The result was a sample of all randomised controlled trials published in this journal series for a 10-year period. HTA journal publications contain the full report of each trial. This might include not only the trial's effectiveness findings, but also an economic evaluation and, in some cases, additional but related work, such as a qualitative study. These separate elements of the project might also be published in other peer-reviewed journals, which have more restrictive word-counts but also have the potential to increase the visibility and discoverability of the research¹⁴. In order to gain a fuller picture of the impact of this set of HTA journal trials, these related publications (effectiveness / efficacy results only) were also included in our sample. These additional, related publications were identified from a combination of sources: first, the trials' project webpages hosted by NIHR; and second, a search in the Science Citation Index (Web of Science).

Citation analysis

1
2
3 Citation analysis represents a conventional and robust approach to gauging a type of research impact. This
4 approach tends to focus on a single funder; uses a single type of research project (e.g. trials) as the unit of analysis;
5 and applies ‘forward tracing’ (identifying publications that cite the index publication)¹⁵. In this case, the aim was
6 to identify publications or documents that cited each HTA journal trial publication. To do this, a search was
7 conducted in September and October 2018 in the Science Citation Index (Web of Science) to identify publications
8 citing the HTA journal trials in our sample. This database was used because it is a highly comprehensive citation
9 index and facilitates searching and downloading of results. The following citation data were then extracted for
10 each HTA journal trial publication, as well as each related journal publication, and entered into Excel spreadsheets
11 (see Supplementary file 1): total number of citations per trial; number of unique Cochrane and non-Cochrane
12 systematic reviews and meta-analyses citing each trial; number of unique policy, practice or guidance documents
13 or publications citing each trial. The two sets of data for the HTA journal publication and any related publication
14 were then integrated (counting only once any systematic reviews and policy documents that cited both the HTA
15 and its related publication). The ‘policy’ publications included any document described as guidance, guidelines,
16 recommendations, position or consensus statements, or similar publication from national bodies, e.g. National
17 Institute of Health and Care Excellence (NICE), or named specialist society, college or association (e.g. European
18 Society of Cardiology, American College of Gastroenterology or the British Thoracic Society). This is not to
19 claim equivalence between the potential impact of guidelines produced by national bodies, such as NICE, and
20 specialist societies, but rather the aim was to capture the meaningful uptake of the trial evidence within different
21 types and levels of publications that have the greatest potential to impact actual practice. Given that such policy
22 and guidance documents can be difficult to find and many will not be catalogued in standard databases, a
23 complementary search was conducted for each trial using the policy score facility of Altmetric.com®, which
24 identifies web-based policy and related documents¹⁶. Altmetrics are alternative indicators of interest relating to
25 scholarly outputs, most notably journal publications. Altmetric.com® are one of the pioneers in the use of
26 altmetrics to provide useful insights into how a piece of research is communicated across the Web, primarily on
27 traditional and social media platforms. In 2014 Altmetric.com® started searching for policy document mentions
28 of research on the web, given such evidence was not indexed in traditional research databases. Altmetric.com®
29 does this by tracking a broad range of policy sources directly from organisational websites. This is not an
30 exhaustive list of policy documents but is updated when new policy sources are identified by Altmetric.com® or
31 their users¹⁷. The policy documents within those websites are then searched for citations of research papers via
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 unique IDs, link searching and text mining. The complete citation data collected were tabulated and descriptive
4 statistics were produced.
5
6
7
8
9

10 *Quantitative content analysis*

11
12
13 The citation analysis provided data on how often each trial had been cited overall, and how often by relevant
14 'secondary outputs', i.e. systematic reviews/meta-analyses, and policy or guidance documents. However, this is a
15 limited metric; as noted above, it does not indicate how the research was used or its possible level of influence on
16 other publications⁸. Greater scrutiny of the citation was therefore required. To do this, quantitative content
17 analysis¹⁸ was conducted on a subset of the total sample in order to determine how these trial publications were
18 actually being used in these two subsets of relevant secondary outputs^{8,19}. All included trials were sampled
19 purposively to select those with extensive, relevant citation data across both types of secondary outputs. This
20 sample was therefore composed of all HTA journal trial publications cited in at least one systematic review *and*
21 at least one policy document, supplemented by related publications in other journals satisfying the same criteria
22 but where the trial was not already identified from the HTA journal publication set. The aim was to compile an
23 extensive and useful set of data for in-depth analysis, representing at least 50% of the whole 10-year sample, in
24 order to test how these trials were actually used within relevant publication types.
25
26
27
28
29
30
31
32
33
34
35
36

37 In the quantitative content analysis, the impact of each published trial on the citing systematic review, policy or
38 guidance document was categorised as either 'instrumental' or 'symbolic'. This terminology is commonly used
39 in the research and policy impact literature^{3,15}. Instrumental use refers to 'the explicit application of research to
40 address a policy problem; where research influences issue identification, policy refinement, definition or
41 implementation in a direct and potentially measurable way ... that is, policymakers are aware that they are using
42 research in this way and there may be evidence supporting claimed instances of use'¹⁴. Symbolic use of a piece
43 of research is when it has been used 'to justify a position or specific action already taken for other reasons or to
44 obtain specific goals based on a predetermined position'¹⁴. In previous studies, the vast majority of citations
45 analysed have been found to be 'symbolic', that is, a 'reference in passing', providing only the most general
46 support for a chosen approach, rather than representing anything more meaningful^{3,19}. In this study, to be
47 categorised as 'instrumental' impact in policy or guidance documents, the trial had to have clear supportive link
48 to a recommendation or statement: it had to be one of only a small number of studies (1, 2, 3 or 4) supporting a
49 recommendation. If this level of influence was not apparent, or the trial reported a finding different from the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 recommendation, then the trial's citation was categorised as 'symbolic' for that piece of guidance. Applying the
4 same principles to citing systematic reviews/meta-analyses, the trial had to be used in the actual synthesis to be
5 categorised as having an 'instrumental' impact, otherwise its impact was categorised as 'symbolic' only.
6
7
8
9

10 11 12 III. RESULTS

13
14 The total number of NIHR-funded randomised controlled trials published in the HTA journal series for the 10
15 years between 2006 and 2015 was n=133. These were all clinical effectiveness or diagnostic accuracy randomised
16 controlled trials, 40 of which were described as pragmatic randomised controlled trials. 119 trials also included a
17 cost-effectiveness analysis or other economic evaluation. Additional elements reported in the HTA journal
18 publications related to the trials in this sample were qualitative (n=20) and observational studies (n=9). Two trials
19 experienced recruitment problems^{20,21}, although both had citation data. Related publications reported the
20 effectiveness results of 82 of these 133 trials in journals other than the HTA journal series. A typical example is
21 provided by the COMICE trial, the effectiveness results of which were published in both the HTA journal^{22,23} and
22 The Lancet¹⁹. There has been a marked increase in the numbers of trials published over this period, although with
23 the odd exception the proportion of trials with both an HTA and related but separate publication has remained
24 fairly stable (Figure 1).
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Figure 1: Numbers of HTA journal trials and numbers with key related publications by year of publication in the**
40 **HTA journal**
41
42
43
44
45

46 *Citation analysis*

47
48
49 The citation data are presented in Table 1 (the complete data sheet is available as Supplementary file 1). The basic
50 mean citation rate per trial was approximately 103. Across both the HTA and related publications, 131/133 (98%)
51 of the trials were cited in either a systematic review or meta-analysis, or in a policy or guidance document; only
52 two trials (2%) were not found in this analysis to be cited in any potentially relevant document²⁴⁻²⁵. 129/133 (97%)
53 trials were found to be cited in one or more systematic reviews or meta-analyses, the vast majority of which were
54 non-Cochrane reviews (84%). 91/133 (68%) of trials were found to be cited in one or more documents of guidance
55
56
57
58
59
60

1
2
3 or policy. The number of citing systematic reviews and meta-analyses per trial ranged from 0 to 44, and policy
4 and guidance documents per trial from 0 to 26.
5
6
7
8
9

10 <Table 1>
11
12
13
14
15

16 The publication of trials' effectiveness findings in journals other than the HTA journal has a clear influence on
17 the citation metrics. These related publications achieve twice the mean number of citing reviews and more than
18 four times the mean number of citing policy/guidance documents than the HTA journal publication: 125 vs 25
19 citations per trial; 7.16 vs 3.32 reviews per trial; 3.59 vs 0.80 policy/guidance documents per trial (Table 1). This
20 is important because the original 82 HTA journal publications for these 82 related publications reflected the mean
21 rates for the 133 HTA journal publication sample as a whole: means of 25.95 vs 25.36 citations, 3.55 vs 3.32
22 reviews, 0.80 vs 0.80 policy/guidance documents. Sixty-six systematic reviews/meta-analyses and 29
23 policy/guidance documents cited both the HTA journal publication and the related publication. When the data
24 from both the HTA journal and their related publications were combined, and only unique systematic reviews and
25 meta-analyses and policy/guidance documents for each trial were counted, 98% of these randomised controlled
26 trials were cited by at least one review (mean 7.18 reviews per trial) and 68% by at least one policy/guidance
27 document (mean 2.75 such documents per trial). The trend is for a decline in the mean number of citing secondary
28 outputs per trial, but this is probably a function of publication date (see Figure 2).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Figure 2: Trends in total citation rates by year of publication in the HTA journal**
46
47
48

49 Altmetric.com® identified a substantial minority of unique policy and guidance documents, which might not
50 otherwise have been identified. For the HTA journal publications, 55 had at least one citing policy/guidance
51 document; 31 were identified exclusively from the Science Citation Index; 15 exclusively from Altmetric.com®;
52 and nine trials had relevant policy and guidance documents identified by both sources. Of the 106 pieces of
53 policy/guidance identified for these 55 HTA journal trial publications, 28 were unique to Altmetric.com®. Of the
54
55
56
57
58
59
60

1
2
3 295 for the related publications, 40 were unique to Altmetric.com®. Altmetric.com® was particularly good at
4 identifying relevant NICE guidance.
5
6
7
8
9

10 *Quantitative content analysis*

11
12
13 This in-depth analysis was performed on a subset of trials (n=68) purposively sampled from both the HTA journal
14 publication and related journal publications that each had citation data from both systematic reviews/meta-
15 analyses *and* policy/guidance documents (see the final column of Table 1). The integrated data for this subset are
16 presented in Table 2.
17
18
19
20
21
22
23

24 <Table 2>
25
26
27
28
29

30 These 68 trials were cited in more than 300 reviews or meta-analyses and were found to be used in the synthesis
31 more than 60% of the time. However, in 38% of these publications the trial and its data were not used in the
32 synthesis at all. Rather the trial was cited only in the Introduction or Discussion or, in some cases, specifically in
33 Cochrane reviews, the trial was cited in the list of excluded studies (failure to satisfy the inclusion criteria). These
34 68 trials were cited in 132 pieces of published policy/guidance, but in 59% of these publications the use of the
35 trial and its data was symbolic only: they had no apparent influence on any recommendation or statement.
36
37
38
39
40
41
42
43
44
45
46
47

48 IV. DISCUSSION

49 Impact is a broad and complex topic involving multiple factors, which can and should be measured and captured
50 in various ways^{3,13,15}, but it is certainly the case that simple citation metrics have limited value: there are significant
51 differences even between medical disciplines and disease areas²⁶. The work conducted here offers a simple,
52 objective measure of the potential instrumental impact of a group of randomised controlled trials. The basic mean
53 citation rate per trial (102.97) is impressive and compares extremely favourably with reported rates for medical
54 and health sciences publications in this period (2006-2015) (mean normative citation rate reported as 33.63 per
55
56
57
58
59
60

1
2
3 publication for 2010)²⁷. However, as noted above, a more useful citation metric is the number of times research is
4 cited in a relevant and genuinely influential manner, i.e. an ‘instrumental’ citation. For randomised controlled
5 trials, one should see their citation in policy documents and in systematic reviews/meta-analyses (specifically, the
6 use of the trial and its data in a synthesis) as fulfilling such criteria.^{3,15} The data reported here for citations within
7 these types of documents are not nearly as impressive as the basic citation rate. However, for systematic reviews
8 and meta-analyses they do suggest that, on average, each of these trials is cited by approximately seven systematic
9 reviews or meta-analyses and its data are used in the synthesis in two thirds of them. While some trials achieved
10 many such citations, and some none, others do reflect this division. For example, the 2009 VULCAN trial HTA
11 journal publication²⁸ was cited by nine reviews: it was used in meta-analysis by two^{29,30}, narrative synthesis by
12 three³¹⁻³³, was cited as an excluded study in a Cochrane review³⁴, and cited only in the Background^{35,36} and
13 Discussion³⁷ in the remaining three reviews.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 These trials were also cited in far fewer policy and guidance documents than reviews, which reflects the general
29 acceptance of the systematic review (of trials) as the gold standard for evidence-based decision-making¹¹. There
30 were certainly many cases where the influence of the trial and its data were clearly instrumental in shaping policy
31 and recommendations both in the UK and internationally. For example, the TRAC trial³⁸ had a strong instrumental
32 impact on the relevant NICE guideline: it was the most influential one of only two trials supporting a
33 recommendation³⁹. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial⁴⁰ was cited as
34 the single most instrumental piece of evidence in an American College of Cardiology/American Heart Association
35 recommendation⁴¹. Such instrumental impact was also achieved by trials with findings of ‘no effect’, i.e. the
36 intervention being tested was found to be no better, in terms of clinical effectiveness, than its comparator. For
37 example, the SABRE trial⁴² found that the intervention was no different from standard care and, as a result,
38 recommendations were changed in Finnish guidance⁴³. This is important because it demonstrates that ‘positive’
39 findings are not necessary for a trial to have instrumental impact. Indeed, it is noteworthy that 39/133 (29%) trials
40 had such so-called ‘negative’ findings, and 27/39 of these were published in related journals also (see
41 Supplementary file 1). The risk of publication bias is clearly much reduced when research is publicly-funded⁴⁴.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
However, in the majority of cases (59%) instrumental influence on policy and guidance was difficult to discern
or was clearly absent; the citation was ‘symbolic’ only. Nevertheless, these data indicate overall that these NIHR-

1
2
3 funded randomised controlled trials achieved impact both on the evidence-base most likely to inform policy
4 decisions (systematic reviews) and on policy documents themselves.
5
6
7
8
9

10 Altmetric.com® was found to be a highly efficient means of identifying unique policy and guidance documents,
11 such as NICE guidelines. Standard web searching, and even the search functions on relevant websites, e.g. the
12 NICE website, does not permit the same efficient identification of potential policy documents. Key organisations
13 like NICE are searched by Altmetric.com® for policy mentions, but their list is not exhaustive. As more national
14 guidance centres and policy documents are added to the Altmetric.com® database, more useful altmetric insights
15 will be made regarding how research is cited within national and international policy. These altmetrics will rely
16 on research outputs being properly cited and linked within subsequent online policy documents.
17
18
19
20
21
22
23
24
25
26

27 Finally, the role played by the separate publication of NIHR-funded trials' key effectiveness findings in journals
28 other than, and in addition to the HTA journal series is unclear. Superficially, these additional publications appear
29 to generate larger numbers of basic citations, as well as comparatively higher citation rates for reviews and policy
30 documents compared with their equivalent HTA journal publications (see Table 1). This is different from other
31 findings in this area⁴⁵ and might demonstrate the value of publishing trial data in journals such as The Lancet and
32 BMJ because they make the data more 'discoverable'. Alternatively, good quality systematic reviews and
33 guidance documents would or should have found the HTA publication and its data anyway. Unfortunately, the
34 data presented here do not allow us to compare citation rates for a particular trial directly across different journals,
35 so it is not possible to reach an unequivocal conclusion on this matter⁴⁵.
36
37
38
39
40
41
42
43
44
45
46
47

48 Limitations

49
50
51 Citation data are evolving all the time and, since this analysis, each trial assessed here will have been cited on
52 more occasions and potentially in more reviews and policy and guidance documents than reported here. These
53 data therefore represent a particular point in time for these trials. It is also possible that a number of citing
54 systematic reviews/meta-analyses and policy/guidance documents were missed by the searches conducted for this
55 study, despite approaches that aimed at comprehensive coverage. However, this was a large sample of randomised
56
57
58
59
60

1
2
3 controlled trials from across a 10-year period, which therefore also took into account **time lags and** potential long-
4 term impact³, included substantial evidence from related publications, and used novel and efficient tools such as
5 Altmetric.com® to identify otherwise difficult to discover citations. As a result, the chance of missing large
6 numbers of reviews and policy documents that might affect the findings of this study in a meaningful way is low.
7
8 The level of scrutiny required to determine levels of impact was substantial, so this is not a rapid form of
9 assessment. However, the assessment of impact in terms of the use of these trials and their data in evidence
10 synthesis and policy is both objective and meaningful. It is the exhaustive identification and quantitative content
11 analysis of key publication and document types to understand impact on a deeper level that represents a real novel
12 and meaningful extension to the existing body of research in this field. There is no reason why this approach and
13 its principles should not apply to other types of health research also. **Additional work might also consider time**
14 **from a trial's publication to its citation in both reviews and policy documents, in order to understand this trajectory**
15 **better. Finally, these trials were country-specific – they were all conducted in the UK - and this in turn might have**
16 **limited their impact. However, as noted above (and as detailed in Supplementary file 1), the trials are not**
17 **infrequently cited in the guidance or policy statements of non-UK countries.**
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 V. CONCLUSIONS

34
35 The instrumental use of a randomised controlled trial in key secondary outputs (systematic reviews and meta-
36 analyses, and policy and guidance documents) represents a single, easily quantifiable but important dimension of
37 impact. This analysis has found that this 10-year sample of randomised controlled trials funded by the NIHR, and
38 published in the HTA journal series (as well as their related publications in other journals), has impressive citation
39 rates and a sizeable proportion are certainly being used in key publications in a genuinely instrumental manner.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Kristensen F, Husereau D, Huic M, et al. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. *Value Health* 2019;22:13-20.
2. Bowden J, Sargent N, Wesselingh S, Size L, Donovan C, Miller C. Measuring research impact: a large cancer research funding programme in Australia. *Health Res Policy Syst*. 2018;16:39.
3. Greenhalgh T, Raftery J, Hanney S, Glover M. Research impact: a narrative review. *BMC Med* 2016;14:78.
4. Buxton M. The payback of 'payback': challenges in assessing research impact. *Res Eval* 2011;20:259-260.
5. Alla K, Hall W, Whiteford H, Head B, Meurk C. How do we define the policy impact of public health research? A systematic review. *Health Res Policy Syst*. 2017;15:84.
6. Aksnes D, Langfeldt L, Wouters P. Citations, Citation Indicators, and Research Quality: An Overview of Basic Concepts and Theories. *SAGE Open* 2019; 9:1.
7. Hutchins B, Yuan X, Anderson J, Santangelo G. Relative Citation Ratio (RCR): A New Metric That Uses Citation Rates to Measure Influence at the Article Level. *PLOS Biol* 2016;19(9):1-25.
8. Newson R, Rychetnik L, King L, Milat A, Bauman A. Does citation matter? Research citation in policy documents as an indicator of research impact - an Australian obesity policy case-study. *Health Res Policy Syst* 2018;16:55.
9. Hanney S, Watt A, Jones T, Metcalf. L. Conducting retrospective impact analysis to inform a medical research charity's funding strategies: the case of Asthma UK. *Allergy Asthma Clin Immunol* 2013;9:17.
10. Raftery J, Hanney S, Greenhalgh T, Glover M, Blatch-Jones A. Models and applications for measuring the impact of health research: update of a systematic review for the Health Technology Assessment programme. *Health Technol Assess* 2016;20:76.
11. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. <http://www.cebm.net/index.aspx?o=5653> (Accessed May 2019).
12. GRADE. Grading of Recommendations Assessment, Development and Evaluation <http://www.gradeworkinggroup.org/> (Accessed 25/07/19).
13. Carroll C, Dickson R, Boland A, Houten R, Walton M. Decision-making by the NICE Interventional Procedures Advisory Committee. *British Journal of Surgery*. 2019; 106: 1769-1774.

14. Guthrie S, Bienkowska-Gibbs T, Manville C, Pollitt A, Kirtley A, Wooding S. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003–13: a multimethod evaluation. *Health Technol Assess* 2015;19:67.
15. Newson R, King L, Rychetnik L, Milat A, Bauman A. Looking both ways: a review of methods for assessing research impacts on policy and the policy utilisation of research. *Health Res Policy Syst* 2018;16:54.
16. Tattersall A, Carroll C. What Can Altmetric.com Tell Us About Policy Citations of Research? An Analysis of Altmetric.com Data for Research Articles from the University of Sheffield. *Frontiers in Research Metrics and Analytics*. 2018:2.
17. Altmetric.com. <https://help.altmetric.com/support/solutions/articles/6000129069-how-does-altmetric-track-policy-documents> 2017 (Accessed 22 November 2019).
18. Neuendorf K. *The Content Analysis Guidebook*. 2nd edition. Los Angeles: Sage; 2017.
19. Carroll C. Measuring academic research impact: creating a citation profile using the conceptual framework for implementation fidelity as a case study. *Scientometrics* 2016;102(2):1329-1340.
20. Speed C, Heaven B, Adamson A, Bond J, Corbett S, et al. LIFELAX - diet and LIFeStyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial. *Health Technol Assess* 2010;14:52.
21. Rogers C, Pike K, Campbell H, et al. Coronary artery bypass grafting in High RISK patients randomised to Off Pump or On Pump Surgery - the CRISP trial. *Health Technol Assess*. 2014;18:44.
22. Turnbull L, Brown S, Olivier C, et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). *Health Technol Assess* 2010;14:1.
23. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. *Lancet* 2010;375:563-571.
24. Carr A, Cooper C, Campbell M, et al. Clinical effectiveness and cost-effectiveness of open and arthroscopic rotator cuff repair: the UK Rotator Cuff Surgery (UKUFF) randomised trial. *Health Technol Assess* 2015;19:80.
25. Blyth A, Maskrey V, Notley C, et al. Effectiveness and economic evaluation of self-help educational materials for the prevention of smoking relapse: randomised controlled trial. *Health Technol Assess*. 2015;19:59.

26. van Eck N, Waltman L, van Raan A, Klautz R, Peul WC. Citation Analysis May Severely Underestimate the Impact of Clinical Research as Compared to Basic Research. *PLOS One* 2013;8(4):e01243.
27. Marx W, Bornmann L. On the casues of subject-specific citation rates in Web of Science. *Scientometrics* 2015;102(2):1823-1827.
28. Michaels J, Campbell W, King B, et al. A prospective randomised controlled trial and economic modelling of antimicrobial silver dressings versus non-adherent control dressings for venous leg ulcers: the VULCAN trial. *Health Technol Assess* 2009;13:56.
29. O'Meara S, Al-Khurdi D, Ologun Y, Ovington L, Martyn-St James M, Richardson R. Antibiotics and antiseptics for venous leg ulcers. *Cochrane Database Syst Rev.* 2014:CD003557.
30. Whitehurst D, Bryan S, Lewis M. Systematic review and empirical comparison of contemporaneous EQ-5D and SF-6D group mean scores. *Med Decis Making* 2011;31:E34-E44.
31. Norman G, Westby M, Rithalia A, Stubbs N, Soares M, Dumville J. Dressings and topical agents for treating venous leg ulcers. *Cochrane Database Syst Rev.* 2018:CD012583.
32. Tricco A, Cogo E, Isaranuwachai W, et al. A systematic review of cost-effectiveness analyses of complex wound interventions reveals optimal treatments for specific wound types. *BMC Med* 2015;13:90.
33. Dissemond J, Böttrich J, Braunwarth H, Hilt J, Wilken P, Münter K. Evidence for silver in wound care - meta-analysis of clinical studies from 2000-2015. *J Dtsch Dermatol Ges.* 2017;15:524-535.
34. Samuel N, Carradice D, Wallace T, Smith G, Chetter I. Endovenous thermal ablation for healing venous ulcers and preventing recurrence. *Cochrane Database Syst Rev.* 2013:CD009494.
35. Cullum N, Liu Z. Therapeutic ultrasound for venous leg ulcers. *Cochrane Database Syst Rev.* 2017:CD001180.
36. Pandor A, Thokala P, Gomersall T, et al. Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation. *Health Technol Assess* 2013;17:32.
37. Leaper D, Münter C, Meaume S, et al. The Use of Biatain Ag in Hard-to-Heal Venous Leg Ulcers: Meta-Analysis of Randomised Controlled Trials. *PLOS One* 2013;8(7):e67083.
38. Forster A, Dickerson J, Young J, et al. A cluster randomised controlled trial and economic evaluation of a structured training programme for caregivers of inpatients after stroke: the TRACS trial. *Health Technol Assess* 2013;17.

- 1
2
3 39. National Institute of Health and Care Excellence (NICE). Transition between inpatient hospital settings
4 and community or care home settings for adults with social care needs. NICE guideline: full version,
5 November 2015. <https://www.nice.org.uk/guidance/ng27/evidence/full-guideline-pdf-2185185565>
6
7 (Accessed 25 July 2019).
8
9
10
11 40. Bradbury A, Adam D, Bell J, et al. Multicentre randomised controlled trial of the clinical and cost-
12 effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for
13 severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia
14 of the Leg (BASIL) trial. *Health Technol Assess* 2010;14:14.
15
16
17
18 41. Gerhard-Herman M, Gornik H, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of
19 Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of
20 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*
21 2017;135:e726-e779.
22
23
24
25
26 42. Everard M, Hind D, Ugonna K, et al. SABRE: a multicentre randomised control trial of nebulised
27 hypertonic saline in infants hospitalised with acute bronchiolitis. *Thorax* 2014;69(12):1105-1112.
28
29
30 43. Tapiainen T, Aittoniemi J, Immonen J, et al. Finnish guidelines for the treatment of laryngitis, wheezing
31 bronchitis and bronchiolitis in children. *Acta Paediatr*. 2016;105(1):44-49.
32
33
34 44. Lundh A, Lexchin J, Mintzes B, Schroll J, Bero L. Industry sponsorship and research outcome. *Cochrane*
35 *Database Syst Rev*. 2017:MR000033.
36
37
38 45. von Elm E, Poglía G, Walder B, Tramer M. Different Patterns of Duplicate Publication An Analysis of
39 Articles Used in Systematic Reviews. *JAMA* 2004;291(8):974-980.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ABSTRACT:
4

5
6 OBJECTIVES:
7

8 Health Technology Assessment (HTA) aims to inform and support healthcare decision-making and trials are part
9 of that process. The purpose of this study was to measure the impact of a sample of trials in a meaningful but
10 robust fashion.
11
12
13

14
15 METHODS: All randomised controlled trials funded and published by the UK National Institute of Health
16 Research (NIHR) in the Health Technology Assessment journals series and other peer-reviewed journals were
17 identified for 2006-2015. Citation analysis was performed for all trials, and quantitative content analysis
18 undertaken on a purposive sample to determine if impact could be categorised as 'instrumental', i.e. having a clear
19 influence on key research and policy publications.
20
21
22
23

24
25 RESULTS:
26

27
28 The search identified 133 relevant trials. Citation rate per trial was 102.97. 129/133 (98%) of trials were cited in
29 one or more systematic reviews or meta-analyses (mean per trial 7.18, range 0-44). Where they were cited, the
30 trials were used in some form of synthesis 63% of the time. 91/133 (68%) of trials were found to be cited in one
31 or more guidance or policy document (mean per trial 2.75, range 0-26), and had an instrumental influence 41%
32 of the time. The publication of these trials' results in journals other than the Health Technology Assessment journal
33 appears to enhance the discoverability of the trial data. Altmetric.com proved to be very useful in identifying
34 unique policy and guidance documents.
35
36
37
38
39
40

41
42 CONCLUSION:
43

44
45 These trials have impressive citation rates and a sizeable proportion are certainly being used in key publications
46 in a genuinely instrumental manner.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

I. INTRODUCTION

Health Technology Assessment (HTA) aims to inform and support healthcare decision-making¹. Randomised controlled trials are part of that process. They have an inherent value in that they provide an answer to a question where previously there had been uncertainty (equipose). However, ‘value’ is a much-debated and multi-dimensional concept and a randomised controlled trial’s value must extend beyond providing an answer to a question. It should have some demonstrable impact too². However, assessing the impact of research presents many problems. First, there are many available models for doing so, but all have limitations^{3,4}. Second, there is the definition of the term ‘impact’ itself. The measurement of impact can range from counting the number of times a piece of research is cited by others, to its generation of social, economic or health benefits beyond academia^{3,5}. The former, the simple citation of research, is now recognised as a rather limited metric of either impact or quality^{6,7}; it does not indicate how the research was used or its possible level of influence on other research⁸. The latter, the demonstration of benefits beyond academia, is undoubtedly more meaningful, but is also more difficult to determine. Consequently, there is potential value in examining not only those publications that are citing the research, but also how they are using it. In this way, it is possible to generate more meaningful data, while also exploring the broader impact of research.

This study aims to show that a particular approach to analysing citation data can provide greater insight into the impact of a particular body of research. In the payback framework of impact, a link is made between the primary and secondary outputs of research, in other words, between the original journal article and its use by other outputs.^{3,9} In the case of randomised controlled trials, relevant secondary outputs include, most obviously, policy and guidance documents, but also systematic reviews and meta-analyses¹⁰, which represent an influential form of evidence in the production of much policy and guidance^{11,12,13}. Indeed, current published research on this topic has recognised that, ‘there is merit in using existing systematic reviews to assess the impact of trials’¹⁰ and that this knowledge gap remains to be filled. The trials funded by the UK National Institute of Health Research (NIHR) represent an obvious sample on which to conduct this work. This funder has previously sought to gauge the impact of the research it funds, for UK HTA projects generally, based on numbers of publications, basic citation analysis or a small number of individual case studies, testing authors’ perceptions of the impact of their research^{10,14}. This has included an evaluation of the use and weighting of some HTA trials in meta-analyses in Cochrane’s reviews¹⁰, but not their use in non-Cochrane reviews, other types of synthesis, or in policy or guidance documents. The aim of the present research is to extend this previous work by quantifying the impact of randomised controlled trials,

published in the NIHR Health Technology Assessment journal, based on the use of these trials in specific types of citing publication: systematic reviews and meta-analyses, and policy and guidance documents.

II. METHODS

Sample

This study is a citation analysis, with quantitative content analysis, of a sample of randomised controlled trials published in the NIHR Health Technology Assessment (HTA) journal. The HTA monograph is a peer-reviewed, open-access journal. Each issue is dedicated to a single project, such as a randomised controlled trial. To be included in the sample for this analysis, the publication had to be a randomised controlled trial funded by the UK NIHR and published in the HTA journal series from 2006 to 2015. A 10-year period of publications was chosen to enable the creation of a sizeable sample with substantial citation data; this would minimise the chance of findings being heavily skewed by results from a single year or a small group of atypical publications, and also controlled for potential long-term impact³. The date limit of 2015 permitted sufficient time for included trials to have generated citations up to the point of this analysis. To identify these trials, a search was conducted in MEDLINE, which fully indexes the HTA journal, for randomised controlled trials on any topic published in the HTA journal series from 2006 to 2015 inclusive. The results were then screened using the inclusion criteria described above and the following publication types were excluded: pilot, exploratory or feasibility trials; and studies evaluating methods of recruitment to trials. The result was a sample of all randomised controlled trials published in this journal series for a 10-year period. HTA journal publications contain the full report of each trial. This might include not only the trial's effectiveness findings, but also an economic evaluation and, in some cases, additional but related work, such as a qualitative study. These separate elements of the project might also be published in other peer-reviewed journals, which have more restrictive word-counts but also have the potential to increase the visibility and discoverability of the research¹⁴. In order to gain a fuller picture of the impact of this set of HTA journal trials, these related publications (effectiveness / efficacy results only) were also included in our sample. These additional, related publications were identified from a combination of sources: first, the trials' project webpages hosted by NIHR; and second, a search in the Science Citation Index (Web of Science).

Citation analysis

1
2
3 Citation analysis represents a conventional and robust approach to gauging a type of research impact. This
4 approach tends to focus on a single funder; uses a single type of research project (e.g. trials) as the unit of analysis;
5 and applies ‘forward tracing’ (identifying publications that cite the index publication)¹⁵. In this case, the aim was
6 to identify publications or documents that cited each HTA journal trial publication. To do this, a search was
7 conducted in September and October 2018 in the Science Citation Index (Web of Science) to identify publications
8 citing the HTA journal trials in our sample. This database was used because it is a highly comprehensive citation
9 index and facilitates searching and downloading of results. The following citation data were then extracted for
10 each HTA journal trial publication, as well as each related journal publication, and entered into Excel spreadsheets
11 (see Supplementary file 1): total number of citations per trial; number of unique Cochrane and non-Cochrane
12 systematic reviews and meta-analyses citing each trial; number of unique policy, practice or guidance documents
13 or publications citing each trial. The two sets of data for the HTA journal publication and any related publication
14 were then integrated (counting only once any systematic reviews and policy documents that cited both the HTA
15 and its related publication). The ‘policy’ publications included any document described as guidance, guidelines,
16 recommendations, position or consensus statements, or similar publication from national bodies, e.g. National
17 Institute of Health and Care Excellence (NICE), or named specialist society, college or association (e.g. European
18 Society of Cardiology, American College of Gastroenterology or the British Thoracic Society). This is not to
19 claim equivalence between the potential impact of guidelines produced by national bodies, such as NICE, and
20 specialist societies, but rather the aim was to capture the meaningful uptake of the trial evidence within different
21 types and levels of publications that have the greatest potential to impact actual practice. Given that such policy
22 and guidance documents can be difficult to find and many will not be catalogued in standard databases, a
23 complementary search was conducted for each trial using the policy score facility of Altmetric.com®, which
24 identifies web-based policy and related documents¹⁶. Altmetrics are alternative indicators of interest relating to
25 scholarly outputs, most notably journal publications. Altmetric.com® are one of the pioneers in the use of
26 altmetrics to provide useful insights into how a piece of research is communicated across the Web, primarily on
27 traditional and social media platforms. In 2014 Altmetric.com® started searching for policy document mentions
28 of research on the web, given such evidence was not indexed in traditional research databases. Altmetric.com®
29 does this by tracking a broad range of policy sources directly from organisational websites. This is not an
30 exhaustive list of policy documents but is updated when new policy sources are identified by Altmetric.com® or
31 their users¹⁷. The policy documents within those websites are then searched for citations of research papers via
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 unique IDs, link searching and text mining. The complete citation data collected were tabulated and descriptive
4 statistics were produced.
5
6
7
8
9

10 *Quantitative content analysis*

11
12
13 The citation analysis provided data on how often each trial had been cited overall, and how often by relevant
14 'secondary outputs', i.e. systematic reviews/meta-analyses, and policy or guidance documents. However, this is a
15 limited metric; as noted above, it does not indicate how the research was used or its possible level of influence on
16 other publications⁸. Greater scrutiny of the citation was therefore required. To do this, quantitative content
17 analysis¹⁸ was conducted on a subset of the total sample in order to determine how these trial publications were
18 actually being used in these two subsets of relevant secondary outputs^{8,19}. All included trials were sampled
19 purposively to select those with extensive, relevant citation data across both types of secondary outputs. This
20 sample was therefore composed of all HTA journal trial publications cited in at least one systematic review *and*
21 at least one policy document, supplemented by related publications in other journals satisfying the same criteria
22 but where the trial was not already identified from the HTA journal publication set. The aim was to compile an
23 extensive and useful set of data for in-depth analysis, representing at least 50% of the whole 10-year sample, in
24 order to test how these trials were actually used within relevant publication types.
25
26
27
28
29
30
31
32
33
34
35
36

37 In the quantitative content analysis, the impact of each published trial on the citing systematic review, policy or
38 guidance document was categorised as either 'instrumental' or 'symbolic'. This terminology is commonly used
39 in the research and policy impact literature^{3,15}. Instrumental use refers to 'the explicit application of research to
40 address a policy problem; where research influences issue identification, policy refinement, definition or
41 implementation in a direct and potentially measurable way ... that is, policymakers are aware that they are using
42 research in this way and there may be evidence supporting claimed instances of use'¹⁴. Symbolic use of a piece
43 of research is when it has been used 'to justify a position or specific action already taken for other reasons or to
44 obtain specific goals based on a predetermined position'¹⁴. In previous studies, the vast majority of citations
45 analysed have been found to be 'symbolic', that is, a 'reference in passing', providing only the most general
46 support for a chosen approach, rather than representing anything more meaningful^{3,19}. In this study, to be
47 categorised as 'instrumental' impact in policy or guidance documents, the trial had to have clear supportive link
48 to a recommendation or statement: it had to be one of only a small number of studies (1, 2, 3 or 4) supporting a
49 recommendation. If this level of influence was not apparent, or the trial reported a finding different from the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 recommendation, then the trial's citation was categorised as 'symbolic' for that piece of guidance. Applying the
4 same principles to citing systematic reviews/meta-analyses, the trial had to be used in the actual synthesis to be
5 categorised as having an 'instrumental' impact, otherwise its impact was categorised as 'symbolic' only.
6
7
8
9

10 11 12 III. RESULTS

13
14 The total number of NIHR-funded randomised controlled trials published in the HTA journal series for the 10
15 years between 2006 and 2015 was n=133. These were all clinical effectiveness or diagnostic accuracy randomised
16 controlled trials, 40 of which were described as pragmatic randomised controlled trials. 119 trials also included a
17 cost-effectiveness analysis or other economic evaluation. Additional elements reported in the HTA journal
18 publications related to the trials in this sample were qualitative (n=20) and observational studies (n=9). Two trials
19 experienced recruitment problems^{20,21}, although both had citation data. Related publications reported the
20 effectiveness results of 82 of these 133 trials in journals other than the HTA journal series. A typical example is
21 provided by the COMICE trial, the effectiveness results of which were published in both the HTA journal^{22,23} and
22 The Lancet¹⁹. There has been a marked increase in the numbers of trials published over this period, although with
23 the odd exception the proportion of trials with both an HTA and related but separate publication has remained
24 fairly stable (Figure 1).
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Figure 1: Numbers of HTA journal trials and numbers with key related publications by year of publication in the**
40 **HTA journal**

41 42 43 44 45 46 *Citation analysis*

47
48
49 The citation data are presented in Table 1 (the complete data sheet is available as Supplementary file 1). The basic
50 mean citation rate per trial was approximately 103. Across both the HTA and related publications, 131/133 (98%)
51 of the trials were cited in either a systematic review or meta-analysis, or in a policy or guidance document; only
52 two trials (2%) were not found in this analysis to be cited in any potentially relevant document²⁴⁻²⁵. 129/133 (97%)
53 trials were found to be cited in one or more systematic reviews or meta-analyses, the vast majority of which were
54 non-Cochrane reviews (84%). 91/133 (68%) of trials were found to be cited in one or more documents of guidance
55
56
57
58
59
60

1
2
3 or policy. The number of citing systematic reviews and meta-analyses per trial ranged from 0 to 44, and policy
4 and guidance documents per trial from 0 to 26.
5
6
7
8
9

10 <Table 1>
11
12
13
14
15

16 The publication of trials' effectiveness findings in journals other than the HTA journal has a clear influence on
17 the citation metrics. These related publications achieve twice the mean number of citing reviews and more than
18 four times the mean number of citing policy/guidance documents than the HTA journal publication: 125 vs 25
19 citations per trial; 7.16 vs 3.32 reviews per trial; 3.59 vs 0.80 policy/guidance documents per trial (Table 1). This
20 is important because the original 82 HTA journal publications for these 82 related publications reflected the mean
21 rates for the 133 HTA journal publication sample as a whole: means of 25.95 vs 25.36 citations, 3.55 vs 3.32
22 reviews, 0.80 vs 0.80 policy/guidance documents. Sixty-six systematic reviews/meta-analyses and 29
23 policy/guidance documents cited both the HTA journal publication and the related publication. When the data
24 from both the HTA journal and their related publications were combined, and only unique systematic reviews and
25 meta-analyses and policy/guidance documents for each trial were counted, 98% of these randomised controlled
26 trials were cited by at least one review (mean 7.18 reviews per trial) and 68% by at least one policy/guidance
27 document (mean 2.75 such documents per trial). The trend is for a decline in the mean number of citing secondary
28 outputs per trial, but this is probably a function of publication date (see Figure 2).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Figure 2: Trends in total citation rates by year of publication in the HTA journal**
46
47
48

49 Altmetric.com® identified a substantial minority of unique policy and guidance documents, which might not
50 otherwise have been identified. For the HTA journal publications, 55 had at least one citing policy/guidance
51 document; 31 were identified exclusively from the Science Citation Index; 15 exclusively from Altmetric.com®;
52 and nine trials had relevant policy and guidance documents identified by both sources. Of the 106 pieces of
53 policy/guidance identified for these 55 HTA journal trial publications, 28 were unique to Altmetric.com®. Of the
54
55
56
57
58
59
60

1
2
3 295 for the related publications, 40 were unique to Altmetric.com®. Altmetric.com® was particularly good at
4 identifying relevant NICE guidance.
5
6
7
8
9

10 *Quantitative content analysis*

11
12
13 This in-depth analysis was performed on a subset of trials (n=68) purposively sampled from both the HTA journal
14 publication and related journal publications that each had citation data from both systematic reviews/meta-
15 analyses *and* policy/guidance documents (see the final column of Table 1). The integrated data for this subset are
16 presented in Table 2.
17
18
19
20
21
22
23
24

25 <Table 2>
26
27
28
29

30 These 68 trials were cited in more than 300 reviews or meta-analyses and were found to be used in the synthesis
31 more than 60% of the time. However, in 38% of these publications the trial and its data were not used in the
32 synthesis at all. Rather the trial was cited only in the Introduction or Discussion or, in some cases, specifically in
33 Cochrane reviews, the trial was cited in the list of excluded studies (failure to satisfy the inclusion criteria). These
34 68 trials were cited in 132 pieces of published policy/guidance, but in 59% of these publications the use of the
35 trial and its data was symbolic only: they had no apparent influence on any recommendation or statement.
36
37
38
39
40
41
42
43
44
45
46
47

48 IV. DISCUSSION

49 Impact is a broad and complex topic involving multiple factors, which can and should be measured and captured
50 in various ways^{3,13,15}, but it is certainly the case that simple citation metrics have limited value: there are significant
51 differences even between medical disciplines and disease areas²⁶. The work conducted here offers a simple,
52 objective measure of the potential instrumental impact of a group of randomised controlled trials. The basic mean
53 citation rate per trial (102.97) is impressive and compares extremely favourably with reported rates for medical
54 and health sciences publications in this period (2006-2015) (mean normative citation rate reported as 33.63 per
55
56
57
58
59
60

1
2
3 publication for 2010)²⁷. However, as noted above, a more useful citation metric is the number of times research is
4 cited in a relevant and genuinely influential manner, i.e. an ‘instrumental’ citation. For randomised controlled
5 trials, one should see their citation in policy documents and in systematic reviews/meta-analyses (specifically, the
6 use of the trial and its data in a synthesis) as fulfilling such criteria.^{3,15} The data reported here for citations within
7 these types of documents are not nearly as impressive as the basic citation rate. However, for systematic reviews
8 and meta-analyses they do suggest that, on average, each of these trials is cited by approximately seven systematic
9 reviews or meta-analyses and its data are used in the synthesis in two thirds of them. While some trials achieved
10 many such citations, and some none, others do reflect this division. For example, the 2009 VULCAN trial HTA
11 journal publication²⁸ was cited by nine reviews: it was used in meta-analysis by two^{29,30}, narrative synthesis by
12 three³¹⁻³³, was cited as an excluded study in a Cochrane review³⁴, and cited only in the Background^{35,36} and
13 Discussion³⁷ in the remaining three reviews.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 These trials were also cited in far fewer policy and guidance documents than reviews, which reflects the general
29 acceptance of the systematic review (of trials) as the gold standard for evidence-based decision-making¹¹. There
30 were certainly many cases where the influence of the trial and its data were clearly instrumental in shaping policy
31 and recommendations both in the UK and internationally. For example, the TRAC trial³⁸ had a strong instrumental
32 impact on the relevant NICE guideline: it was the most influential one of only two trials supporting a
33 recommendation³⁹. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial⁴⁰ was cited as
34 the single most instrumental piece of evidence in an American College of Cardiology/American Heart Association
35 recommendation⁴¹. Such instrumental impact was also achieved by trials with findings of ‘no effect’, i.e. the
36 intervention being tested was found to be no better, in terms of clinical effectiveness, than its comparator. For
37 example, the SABRE trial⁴² found that the intervention was no different from standard care and, as a result,
38 recommendations were changed in Finnish guidance⁴³. This is important because it demonstrates that ‘positive’
39 findings are not necessary for a trial to have instrumental impact. Indeed, it is noteworthy that 39/133 (29%) trials
40 had such so-called ‘negative’ findings, and 27/39 of these were published in related journals also (see
41 Supplementary file 1). The risk of publication bias is clearly much reduced when research is publicly-funded⁴⁴.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
However, in the majority of cases (59%) instrumental influence on policy and guidance was difficult to discern
or was clearly absent; the citation was ‘symbolic’ only. Nevertheless, these data indicate overall that these NIHR-

1
2
3 funded randomised controlled trials achieved impact both on the evidence-base most likely to inform policy
4 decisions (systematic reviews) and on policy documents themselves.
5
6
7
8
9

10 Altmetric.com® was found to be a highly efficient means of identifying unique policy and guidance documents,
11 such as NICE guidelines. Standard web searching, and even the search functions on relevant websites, e.g. the
12 NICE website, does not permit the same efficient identification of potential policy documents. Key organisations
13 like NICE are searched by Altmetric.com® for policy mentions, but their list is not exhaustive. As more national
14 guidance centres and policy documents are added to the Altmetric.com® database, more useful altmetric insights
15 will be made regarding how research is cited within national and international policy. These altmetrics will rely
16 on research outputs being properly cited and linked within subsequent online policy documents.
17
18
19
20
21
22
23
24
25
26

27 Finally, the role played by the separate publication of NIHR-funded trials' key effectiveness findings in journals
28 other than, and in addition to the HTA journal series is unclear. Superficially, these additional publications appear
29 to generate larger numbers of basic citations, as well as comparatively higher citation rates for reviews and policy
30 documents compared with their equivalent HTA journal publications (see Table 1). This is different from other
31 findings in this area⁴⁵ and might demonstrate the value of publishing trial data in journals such as The Lancet and
32 BMJ because they make the data more 'discoverable'. Alternatively, good quality systematic reviews and
33 guidance documents would or should have found the HTA publication and its data anyway. Unfortunately, the
34 data presented here do not allow us to compare citation rates for a particular trial directly across different journals,
35 so it is not possible to reach an unequivocal conclusion on this matter⁴⁵.
36
37
38
39
40
41
42
43
44
45
46
47

48 Limitations

49
50
51 Citation data are evolving all the time and, since this analysis, each trial assessed here will have been cited on
52 more occasions and potentially in more reviews and policy and guidance documents than reported here. These
53 data therefore represent a particular point in time for these trials. It is also possible that a number of citing
54 systematic reviews/meta-analyses and policy/guidance documents were missed by the searches conducted for this
55 study, despite approaches that aimed at comprehensive coverage. However, this was a large sample of randomised
56
57
58
59
60

1
2
3 controlled trials from across a 10-year period, which therefore also took into account **time lags and** potential long-
4 term impact³, included substantial evidence from related publications, and used novel and efficient tools such as
5 Altmetric.com® to identify otherwise difficult to discover citations. As a result, the chance of missing large
6 numbers of reviews and policy documents that might affect the findings of this study in a meaningful way is low.
7
8 The level of scrutiny required to determine levels of impact was substantial, so this is not a rapid form of
9 assessment. However, the assessment of impact in terms of the use of these trials and their data in evidence
10 synthesis and policy is both objective and meaningful. It is the exhaustive identification and quantitative content
11 analysis of key publication and document types to understand impact on a deeper level that represents a real novel
12 and meaningful extension to the existing body of research in this field. There is no reason why this approach and
13 its principles should not apply to other types of health research also. **Additional work might also consider time**
14 **from a trial's publication to its citation in both reviews and policy documents, in order to understand this trajectory**
15 **better. Finally, these trials were country-specific – they were all conducted in the UK - and this in turn might have**
16 **limited their impact. However, as noted above (and as detailed in Supplementary file 1), the trials are not**
17 **infrequently cited in the guidance or policy statements of non-UK countries.**
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 V. CONCLUSIONS

34
35 The instrumental use of a randomised controlled trial in key secondary outputs (systematic reviews and meta-
36 analyses, and policy and guidance documents) represents a single, easily quantifiable but important dimension of
37 impact. This analysis has found that this 10-year sample of randomised controlled trials funded by the NIHR, and
38 published in the HTA journal series (as well as their related publications in other journals), has impressive citation
39 rates and a sizeable proportion are certainly being used in key publications in a genuinely instrumental manner.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Kristensen F, Husereau D, Huic M, et al. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. *Value Health* 2019;22:13-20.
2. Bowden J, Sargent N, Wesselingh S, Size L, Donovan C, Miller C. Measuring research impact: a large cancer research funding programme in Australia. *Health Res Policy Syst*. 2018;16:39.
3. Greenhalgh T, Raftery J, Hanney S, Glover M. Research impact: a narrative review. *BMC Med* 2016;14:78.
4. Buxton M. The payback of 'payback': challenges in assessing research impact. *Res Eval* 2011;20:259-260.
5. Alla K, Hall W, Whiteford H, Head B, Meurk C. How do we define the policy impact of public health research? A systematic review. *Health Res Policy Syst*. 2017;15:84.
6. Aksnes D, Langfeldt L, Wouters P. Citations, Citation Indicators, and Research Quality: An Overview of Basic Concepts and Theories. *SAGE Open* 2019; 9:1.
7. Hutchins B, Yuan X, Anderson J, Santangelo G. Relative Citation Ratio (RCR): A New Metric That Uses Citation Rates to Measure Influence at the Article Level. *PLOS Biol* 2016;19(9):1-25.
8. Newson R, Rychetnik L, King L, Milat A, Bauman A. Does citation matter? Research citation in policy documents as an indicator of research impact - an Australian obesity policy case-study. *Health Res Policy Syst* 2018;16:55.
9. Hanney S, Watt A, Jones T, Metcalf. L. Conducting retrospective impact analysis to inform a medical research charity's funding strategies: the case of Asthma UK. *Allergy Asthma Clin Immunol* 2013;9:17.
10. Raftery J, Hanney S, Greenhalgh T, Glover M, Blatch-Jones A. Models and applications for measuring the impact of health research: update of a systematic review for the Health Technology Assessment programme. *Health Technol Assess* 2016;20:76.
11. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. <http://www.cebm.net/index.aspx?o=5653> (Accessed May 2019).
12. GRADE. Grading of Recommendations Assessment, Development and Evaluation <http://www.gradeworkinggroup.org/> (Accessed 25/07/19).
13. Carroll C, Dickson R, Boland A, Houten R, Walton M. Decision-making by the NICE Interventional Procedures Advisory Committee. *British Journal of Surgery*. 2019; 106: 1769-1774.

14. Guthrie S, Bienkowska-Gibbs T, Manville C, Pollitt A, Kirtley A, Wooding S. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003–13: a multimethod evaluation. *Health Technol Assess* 2015;19:67.
15. Newson R, King L, Rychetnik L, Milat A, Bauman A. Looking both ways: a review of methods for assessing research impacts on policy and the policy utilisation of research. *Health Res Policy Syst* 2018;16:54.
16. Tattersall A, Carroll C. What Can Altmetric.com Tell Us About Policy Citations of Research? An Analysis of Altmetric.com Data for Research Articles from the University of Sheffield. *Frontiers in Research Metrics and Analytics*. 2018:2.
17. Altmetric.com. <https://help.altmetric.com/support/solutions/articles/6000129069-how-does-altmetric-track-policy-documents> 2017 (Accessed 22 November 2019).
18. Neuendorf K. *The Content Analysis Guidebook*. 2nd edition. Los Angeles: Sage; 2017.
19. Carroll C. Measuring academic research impact: creating a citation profile using the conceptual framework for implementation fidelity as a case study. *Scientometrics* 2016;102(2):1329-1340.
20. Speed C, Heaven B, Adamson A, Bond J, Corbett S, et al. LIFELAX - diet and LIFeStyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial. *Health Technol Assess* 2010;14:52.
21. Rogers C, Pike K, Campbell H, et al. Coronary artery bypass grafting in High RiSk patients randomised to Off Pump or On Pump Surgery - the CRISP trial. *Health Technol Assess*. 2014;18:44.
22. Turnbull L, Brown S, Olivier C, et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). *Health Technol Assess* 2010;14:1.
23. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. *Lancet* 2010;375:563-571.
24. Carr A, Cooper C, Campbell M, et al. Clinical effectiveness and cost-effectiveness of open and arthroscopic rotator cuff repair: the UK Rotator Cuff Surgery (UKUFF) randomised trial. *Health Technol Assess* 2015;19:80.
25. Blyth A, Maskrey V, Notley C, et al. Effectiveness and economic evaluation of self-help educational materials for the prevention of smoking relapse: randomised controlled trial. *Health Technol Assess*. 2015;19:59.

- 1
- 2
- 3 26. van Eck N, Waltman L, van Raan A, Klautz R, Peul WC. Citation Analysis May Severely Underestimate
- 4 the Impact of Clinical Research as Compared to Basic Research. *PLOS One* 2013;8(4):e01243.
- 5
- 6
- 7 27. Marx W, Bornmann L. On the casues of subject-specific citation rates in Web of Science. *Scientometrics*
- 8 2015;102(2):1823-1827.
- 9
- 10
- 11 28. Michaels J, Campbell W, King B, et al. A prospective randomised controlled trial and economic
- 12 modelling of antimicrobial silver dressings versus non-adherent control dressings for venous leg ulcers:
- 13 the VULCAN trial. *Health Technol Assess* 2009;13:56.
- 14
- 15
- 16 29. O'Meara S, Al-Khurdi D, Ologun Y, Ovington L, Martyn-St James M, Richardson R. Antibiotics and
- 17 antiseptics for venous leg ulcers. *Cochrane Database Syst Rev.* 2014:CD003557.
- 18
- 19
- 20 30. Whitehurst D, Bryan S, Lewis M. Systematic review and empirical comparison of contemporaneous EQ-
- 21 5D and SF-6D group mean scores. *Med Decis Making* 2011;31:E34-E44.
- 22
- 23
- 24 31. Norman G, Westby M, Rithalia A, Stubbs N, Soares M, Dumville J. Dressings and topical agents for
- 25 treating venous leg ulcers. *Cochrane Database Syst Rev.* 2018:CD012583.
- 26
- 27
- 28 32. Tricco A, Cogo E, Isaranuwachai W, et al. A systematic review of cost-effectiveness analyses of
- 29 complex wound interventions reveals optimal treatments for specific wound types. *BMC Med*
- 30 2015;13:90.
- 31
- 32
- 33 33. Dissemond J, Böttrich J, Braunwarth H, Hilt J, Wilken P, Münter K. Evidence for silver in wound care -
- 34 meta-analysis of clinical studies from 2000-2015. *J Dtsch Dermatol Ges.* 2017;15:524-535.
- 35
- 36
- 37 34. Samuel N, Carradice D, Wallace T, Smith G, Chetter I. Endovenous thermal ablation for healing venous
- 38 ulcers and preventing recurrence. *Cochrane Database Syst Rev.* 2013:CD009494.
- 39
- 40
- 41 35. Cullum N, Liu Z. Therapeutic ultrasound for venous leg ulcers. *Cochrane Database Syst Rev.*
- 42 2017:CD001180.
- 43
- 44
- 45 36. Pandor A, Thokala P, Gomersall T, et al. Home telemonitoring or structured telephone support
- 46 programmes after recent discharge in patients with heart failure: systematic review and economic
- 47 evaluation. *Health Technol Assess* 2013;17:32.
- 48
- 49
- 50
- 51 37. Leaper D, Münter C, Meaume S, et al. The Use of Biatain Ag in Hard-to-Heal Venous Leg Ulcers: Meta-
- 52 Analysis of Randomised Controlled Trials. *PLOS One* 2013;8(7):e67083.
- 53
- 54
- 55 38. Forster A, Dickerson J, Young J, et al. A cluster randomised controlled trial and economic evaluation of
- 56 a structured training programme for caregivers of inpatients after stroke: the TRACS trial. *Health*
- 57 *Technol Assess* 2013;17.
- 58
- 59
- 60

- 1
2
3 39. National Institute of Health and Care Excellence (NICE). Transition between inpatient hospital settings
4 and community or care home settings for adults with social care needs. NICE guideline: full version,
5 November 2015. <https://www.nice.org.uk/guidance/ng27/evidence/full-guideline-pdf-2185185565>
6
7 (Accessed 25 July 2019).
8
9
10
11 40. Bradbury A, Adam D, Bell J, et al. Multicentre randomised controlled trial of the clinical and cost-
12 effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for
13 severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia
14 of the Leg (BASIL) trial. *Health Technol Assess* 2010;14:14.
15
16
17
18 41. Gerhard-Herman M, Gornik H, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of
19 Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of
20 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*
21 2017;135:e726-e779.
22
23
24
25
26 42. Everard M, Hind D, Ugonna K, et al. SABRE: a multicentre randomised control trial of nebulised
27 hypertonic saline in infants hospitalised with acute bronchiolitis. *Thorax* 2014;69(12):1105-1112.
28
29
30 43. Tapiainen T, Aittoniemi J, Immonen J, et al. Finnish guidelines for the treatment of laryngitis, wheezing
31 bronchitis and bronchiolitis in children. *Acta Paediatr*. 2016;105(1):44-49.
32
33
34 44. Lundh A, Lexchin J, Mintzes B, Schroll J, Bero L. Industry sponsorship and research outcome. *Cochrane*
35 *Database Syst Rev*. 2017:MR000033.
36
37
38 45. von Elm E, Poggia G, Walder B, Tramer M. Different Patterns of Duplicate Publication An Analysis of
39 Articles Used in Systematic Reviews. *JAMA* 2004;291(8):974-980.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Numbers of HTA journal trials and numbers with key related publications by year of publication in the HTA journal

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2: Trends in total citation rates by year of publication in the HTA journal

Table 1: Citation data for trials from HTA journal publications and related publications

Trials	Total citations	Mean (range) per trial	Trials cited by ≥ 1 review Total n=	Percentage of Cochrane reviews Total n=	Percentage of Non-Cochrane reviews Total n=	Mean (range) per trial	Trials cited by ≥ 1 policy documents Total n=	Mean number of policy documents per trial	Trials with ≥ 1 systematic review and ≥ 1 policy documents Total n=
HTA journal									
133	3373	25.36 (1-106)	117/133 (88%) n=441	19% n=84	81% n=357	3.32 (0-12)	55/133 (41%) n=106	0.80 (0-6)	49
HTA publications with related publications in other journals (one per trial)									
82	10322	125.88 (1-1286)	76/82 (93%) n=587	16% n=92	84% n=495	7.16 (0-34)	68/82 (83%) n=294	3.59 (0-26)	19

Trials	Total citations	Mean (range) per trial	Trials cited by ≥1 review Total n=	Percentage of Cochrane reviews Total n=	Percentage of Non-Cochrane reviews Total n=	Mean (range) per trial		Trials cited by ≥1 policy documents Total n=	Mean number of policy documents per trial	Trials with ≥1 systematic review and ≥1 policy documents Total n=
Total across all publications (HTA journal publication and any related publications: 216 publications relating to 134 trials)										
†	*13695	102.97 (1-1286)	129/133 (98%) n=962	16% n=156	84% n=806	7.18 (0-44)		91/133 (68%) n=374	2.75 (0-26)	68

*Includes double-counting of publications that cite both the HTA and the related publication †Figures reported here are numbers of unique reviews and policy/guidance documents

Table 2: Use of trials published in the HTA journal, and related publications, in reviews and policy documents

Trials	Number of unique citing reviews	Used in meta-analysis or network meta-analysis	Used in narrative synthesis	Not used in synthesis		Number of unique citing policy documents	Instrumental	Symbolic
HTA journal								
49	208	53 (25%)	82 (39%)	73 (35%)		88	38 (43%)	50 (57%)
Related publications in other journals								
19	104	40 (38%)	20 (19%)	44 (42%)		44	16 (36%)	28 (64%)
Totals across all publications								
68	312	93 (30%)	102 (33%)	117 (38%)		132	54 (41%)	78 (59%)

Responses to reviewers

Reviewer 1	Response
A concept map of impact and value would communicate the researcher's intended meaning for the interrelationship of these with HTAs, and the NIHR.	We have not made this revision as we are not entirely sure what is being proposed by the reviewer, especially as all reference to 'value' was removed from the manuscript in the previous revision (except for two sentences early in the Introduction).
As therapy area/medical specialty also influences the quantity and quality of citation (e.g. cardiology-related HTAs would get more citations than a radiology-related HTA), there should be a way of controlling/adjusting for this. Perhaps a field specific sensitivity analysis?	<p>We agree that this is an interesting idea: to analyse the relative citation rates for distinct specialities. However, there is no universally-accepted list of medical specialities. We conducted a pilot categorisation on the 29 trials published in 2015 using the UK Medical Schools Council's list of medical specialities. The potential categories for this sample of trials were: Medicine (n=13); Psychiatry (n=4); Surgery (n=3); General Practice (n=3); Public Health (n=2); Clinical Oncology (n=1); Clinical Radiology (n=1); Paediatrics (n=1). These specialities are quite broad – arguably too broad to be informative.</p> <p>The 13 trials categorised under Medicine could be further categorised by a range of sub-specialities, including cardiology, genitourinary medicine, geriatrics, pharmaceutical medicine, renal medicine, respiratory medicine, and stroke medicine.</p> <p>The specialities of Surgery and Psychiatry could be equally sub-divided.</p> <p>If this was conducted for the whole sample, the result would be a large number of (sub)specialities, each with between only 1 and 5 trials, for which citation numbers would then be extracted from the Supplementary file. Given that many would have only 1 or 2 trials, it would not be possible to infer any meaningful comparative data regarding the relative 'impact' of trials of different specialities. As a result, we hope that you agree that this proposed analysis and revision need not be conducted.</p>
Is the NIHR's remit for a specific country a potential limiting factor in its impact? Country-specific audience may also play a role in quantifying the influence of a publication on policies	This is an interesting point, thank you, and related text has now been added to the Limitations, p.11.
Time from publication to citation would also be a useful metric, particularly since the study looked at a slice of studies from 2006 to 2015. The impact of published studies may be time-sensitive as well.	We agree that this would be interesting, but would require substantial additional work to identify the first review and the first policy citation for each of the 133 trials (even just for the HTA journal publication alone). This cannot be completed in the time available for this revision. As a result, we have added a comment about this metric in the Limitations, p.11.
Reviewer 2	
Well done, the amended version is much improved.	No action needed

<https://docs.google.com/spreadsheets/d/14VLaDgju84Aq5QntGt4PK7pi7pymHmA/edit#gid=166818731>

CONFIDENTIAL - NOT FOR DISTRIBUTION

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60